356 related articles for article (PubMed ID: 24972708)
41. Certolizumab pegol for the treatment of Crohn's disease.
Sandborn WJ; Feagan BG; Stoinov S; Honiball PJ; Rutgeerts P; Mason D; Bloomfield R; Schreiber S;
N Engl J Med; 2007 Jul; 357(3):228-38. PubMed ID: 17634458
[TBL] [Abstract][Full Text] [Related]
42. Certolizumab pegol in rheumatoid arthritis: current update.
Fechtenbaum M; Md Yusof MY; Emery P
Expert Opin Biol Ther; 2014 Jun; 14(6):841-50. PubMed ID: 24654999
[TBL] [Abstract][Full Text] [Related]
43. Certolizumab: efficacy and safety profile of a novel pegylated TNF-alpha blocking agent.
Lubrano E; Spadaro A
Acta Biomed; 2011 Apr; 82(1):26-34. PubMed ID: 22069953
[TBL] [Abstract][Full Text] [Related]
44. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
Sandborn WJ; Schreiber S; Feagan BG; Rutgeerts P; Younes ZH; Bloomfield R; Coteur G; Guzman JP; D'Haens GR
Clin Gastroenterol Hepatol; 2011 Aug; 9(8):670-678.e3. PubMed ID: 21642014
[TBL] [Abstract][Full Text] [Related]
45. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.
Bykerk VP; Cush J; Winthrop K; Calabrese L; Lortholary O; de Longueville M; van Vollenhoven R; Mariette X
Ann Rheum Dis; 2015 Jan; 74(1):96-103. PubMed ID: 24092417
[TBL] [Abstract][Full Text] [Related]
46. Profile of certolizumab and its potential in the treatment of psoriatic arthritis.
Chimenti MS; Saraceno R; Chiricozzi A; Giunta A; Chimenti S; Perricone R
Drug Des Devel Ther; 2013; 7():339-48. PubMed ID: 23620660
[TBL] [Abstract][Full Text] [Related]
47. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease.
Feagan BG; Coteur G; Tan S; Keininger DL; Schreiber S
Am J Gastroenterol; 2009 Aug; 104(8):1976-83. PubMed ID: 19471252
[TBL] [Abstract][Full Text] [Related]
48. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
Strand V; Mease P; Burmester GR; Nikaï E; Coteur G; van Vollenhoven R; Combe B; Keystone EC; Kavanaugh A
Arthritis Res Ther; 2009; 11(6):R170. PubMed ID: 19909548
[TBL] [Abstract][Full Text] [Related]
49. Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies.
Takeuchi T; Yamamoto K; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
Mod Rheumatol; 2015 Jan; 25(1):11-20. PubMed ID: 24842476
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
Landewé R; Braun J; Deodhar A; Dougados M; Maksymowych WP; Mease PJ; Reveille JD; Rudwaleit M; van der Heijde D; Stach C; Hoepken B; Fichtner A; Coteur G; de Longueville M; Sieper J
Ann Rheum Dis; 2014 Jan; 73(1):39-47. PubMed ID: 24013647
[TBL] [Abstract][Full Text] [Related]
51. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.
Bi L; Li Y; He L; Xu H; Jiang Z; Wang Y; Li X; Wei W; Gu J; Wang G; Zhang Z; Zhou B; Liu Y; Wu Z; Liu H; He D; Lv Z; Li Z; Zuo X; Dong L; Wu H; Zhang H; Chen H; Bao C; Zhang Z; Zhang M; Song H; Zheng Y; Jiang L; Liu X; Boehnlein M; Dunkel J; Shao J; Harris K; Li Z
Clin Exp Rheumatol; 2019; 37(2):227-234. PubMed ID: 30183595
[TBL] [Abstract][Full Text] [Related]
53. Certolizumab pegol in the treatment of Crohn's disease.
Ferrante M; Vermeire S; Rutgeerts P
Expert Opin Biol Ther; 2013 Apr; 13(4):595-605. PubMed ID: 23451881
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.
Tun GS; Lobo AJ
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):317-27. PubMed ID: 25586216
[TBL] [Abstract][Full Text] [Related]
56. Certolizumab pegol: in rheumatoid arthritis.
Duggan ST; Keam SJ
BioDrugs; 2009; 23(6):407-17. PubMed ID: 19894782
[TBL] [Abstract][Full Text] [Related]
57. Certolizumab pegol for the treatment of rheumatoid arthritis.
Horton S; Walsh C; Emery P
Expert Opin Biol Ther; 2012 Feb; 12(2):235-49. PubMed ID: 22165979
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
[TBL] [Abstract][Full Text] [Related]
59. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
[TBL] [Abstract][Full Text] [Related]
60. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
Hanauer SB; Panes J; Colombel JF; Bloomfield R; Schreiber S; Sandborn WJ
Aliment Pharmacol Ther; 2010 Aug; 32(3):384-93. PubMed ID: 20491747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
